Other Events

< 2020 >
July
Sun
Mon
Tue
Wed
Thu
Fri
Sat
June
June
June
1
  • July 1: Biopharma Companies Amid COVID-19
    10:00 am-11:30 pm
    2020.07.01

    Having experienced significant challenges after the outbreak of COVID-19, the healthcare industry in China is on the way to recovery. Companies are facing the “new normal” and adapting to the new dynamics. How is the biopharma industry, in particular, dealing with the crisis and driving growth and innovation going forward? AmCham Shanghai Healthcare Committee invites you to a discussion on how the biopharma companies are manging the risks, accelerating the digital transformation and innovation, and what are the latest investment trends in biopharma on July 1st, from 10:00 am to 11:30 am. The session consists of presentations as well as a panel discussion. The discussion will be facilitated by Greg Scott, Founder & Chairman of ChinaBio® Group and the Chair of AmCham Shanghai Healthcare Committee.

    Read More

    Speakers

    William Cao-Founder, Chairman and CEO of Gracell Biotechnologies Group

    Fangning Zhang-Partner,  Greater China Pharma and MedTech practice, at McKinsey & Company

    Greg Scott-Founder and Chairman of ChinaBio® Group

    Yingjie Wu-Head at Roche Pharma Partnering China

  • 7月1日:生物制药公司COVID-19
    11:11 am
    2020.07.01

    COVID-19爆发后,中国医疗行业面临严峻挑战,正在复苏。 企业正面临着”新常态”,并适应了新的动态。 特别是生物制药行业如何应对危机,推动增长和创新向前发展? 上海美国商会医疗委员会邀请您参加7月1日上午10:00至11:30讨论生物制药公司如何控制风险、加速数字化转型和创新,以及生物制药的最新投资趋势。 会议包括专题介绍和小组讨论。 中国生物集团创始人兼董事长格雷格·斯科特(Greg Scott)®集团创始人兼董事长,以及上海美国商会医疗委员会主席。

    阅读更多

    扬声器

    William Cao– 格雷斯尔生物技术集团董事长兼首席执行官

    张方宁 – 麦肯锡公司大中华制药和医疗技术业务合伙人

    格雷格·斯科特 – 中国生物集团创始人®董事长

    吴英杰 – 罗氏制药合作中国负责人

2
  • July 2: The global medical project of Meibo Medical!
    All day
    2020.07.02

    On July 2 (Thursday), Beijing time, from 15:30 to 17:00, the three heavy-duty projects of the European road cloud roadshow of the Meibo Medical Health Global Project will be on-site roadshows. The roadshow registration channel has been opened. Please scan the code to register. At the same time, the second session of the Chinese project will also be held in July.

    Read more

    Project Title: Functional Healing Vaccine for Hepatitis B-Viravaxx is developing VVX001 as a therapeutic vaccine for chronic hepatitis B, aimed at achieving a functional cure. This product is different from other similar products in that the PreS1 component of the large surface antigen triggers the production of antibodies against the virus attachment site. It has been shown that antisera from immunized human subjects can prevent hepatitis B virus (neutralizing antibodies) from infecting cells.

    Project Name: Bispecific Antibody Immunotherapy-Interceptinsrl is an immuno-oncology company located in Verona, Italy. The company is preparing to enter the clinical development stage of its main product INT001, which is a novel antibody-drug conjugate (ADC) that uses two antibodies combined with Pseudomonas exotoxin in a bispecific preparation. Chain recombinant antibody fragments.

    Project name: New vaccine adjuvant platform technology-CyTuVax has developed and clinically tested the new vaccine adjuvant platform technology, which has been patented in the European Union, the United States (US10,639,367B2) and Canada. Adjuvant technology uses aggregated cytokines in the reservoir as adjuvants, which can be combined with any viral/bacterial antigen or mixed with existing vaccines.

  • 7月2日:美博医疗全球医疗项目!
    All day
    2020.07.02

    北京时间7月2日(星期四)15:30-17:00,美柏医健全球项目云路演欧洲专场3个重磅项目将现场路演,现路演报名通道已经开启,请扫码报名。同时,华人项目专场第二场也将在7月进行。 现路演报名通道已经开启, 请扫码报名。 同时,华人项目专场第二场也将在7月进行。

    详情请点击

    项目名称:乙型肝炎功能治疗疫苗 – Viravaxx正在开发VVX001作为慢性乙型肝炎的治疗疫苗,旨在实现功能治疗。 本产品不同于其他类似产品,因为大型表面抗原的 PreS1 成分触发了针对病毒附件位的抗体的产生。 研究表明,免疫人类受试者的抗血清可以防止乙型肝炎病毒(中和抗体)感染细胞。

    项目名称:双特异性抗体免疫疗法 – 拦截是一家位于意大利维罗纳的免疫肿瘤学公司。 该公司正准备为其主要产品INT001进入临床开发阶段,该产品是一种使用两种抗体的新型抗体-药物偶联物(ADC)与假单胞菌外毒素结合在双特异性制剂中的 单链重组抗体片段

    项目名称:新疫苗辅助平台技术-CyTuVax已开发和临床测试新的疫苗辅助平台技术,该技术已在欧洲、美国(US10,639,367B2)和加拿大获得专利。 佐剂技术将聚集的细胞因子应用在储库中作为佐剂,这些佐剂可与任何病毒/细菌抗原结合或与现有疫苗混合

3
4
5
6
7
  • BioCon2020第七届国际生物药大会暨生物技术仪器设备与试剂展览会
    All day
    2020.07.07-2020.07.09

    时间: 2020.07.07 ~ 2020.07.09

    在接轨国际ICH的背景下,中国的生物药产业化进入到了关键时刻:如何开发下一代新型治疗性生物制品?如何实现差异化生物创新药(新型抗体–双抗/多抗,纳米抗体,ADC、细胞治疗制品、重组蛋白药物等品类)布局、研发与申报?如何在满足监管的条件下实现生物制品的工艺改进与工艺变更?如何加快生物创新药与类似药临床开发?生物药大规模生产与厂房建设需要考虑哪些因素?

    从新药发现到成药性开发,从实验室到产业化,从临床前开发到临床开发,从工艺开发迈向商业化生产,从工艺改进到工艺变更,从管线立项到产品上市等全周期全流程,为中国生物医药产业搭建国内外政策研讨、技术交流、产品展示、项目合作的综合性专业平台,共探行业核心趋势,推动生物医药产业全速前进!

    Biocon2020嘉宾(部分)

    • 陈志南:中国工程院院士,“重大新药创制”国家科技重大专项技术副总师
    • 王亚宁:FDA临床药理审评部定量药理学审评室主任
    • 苏冰:上海市免疫学研究所所长
    • 储以微:复旦大学生物医学研究院党委书记
    • 严景华:中国科学院微生物研究所研究员
    • 任进:中国科学院上海药物研究所药物安全评价研究中心主任

8
  • 7月8日:COVID-19:2021年重塑生物技术
    11:00 am-12:00 pm
    2020.07.08

    当全球生物制药领导者为COVID-19世界制定应急计划和构建方案时,许多人仍然想知道:2021年会是什么样子?
    在这个独家网络研讨会系列的第 2 部分中,BioCentury 和 McKinsey & Co. 讨论了最近一项生物世纪行业调查的主要结果,该调查对生物制药公司而言,2021 年看起来将有所不同。 从预算、临床试验、交易和融资到供应链,COVID-19 从根本上改变了生物制药行业在 2021 年及以后的运作方式。
    在初步讨论之后,BioCentury和麦肯锡将召集一个生物技术C-Suite小组,讨论调查结果以及2021年行业预期。

    会议主席
    西蒙妮·菲什本,博士 – 副总裁兼总编辑/生物世纪公司。
    豪尔赫·桑托斯·达席尔瓦 – 合伙人/麦肯锡公司

    小组成员:
    巴伊贾·贾拉尔,博士 – 首席执行官/免疫核心

9
10
11
  • July 11: 2020 Chippu Summit, the future of the health industry in an epidemic era
    All day
    2020.07.11

    The health industry is considered to be the eternal sunrise industry that can best resist the economic cycle, but because it is closely related to national policies and social livelihood, it also means that the threshold for innovation and entrepreneurship is higher.

    “The health industry needs an opportunity to collect value innovation cases and provide investors and entrepreneurs with inspiration for the future.”.

    In this rapidly changing era and current situation, you will see the thinking of the leaders in the health industry:
    • How to judge the development trend of the industry and make rapid progress?
    • How to face the trend of industrial transformation and rebirth?
    • How to use the development wave of the times to break and extend?
    • How to improve the industrial value system and break the cocoon into a butterfly?
    2020 Chippu Summit, you will meet this group of people here and join this group of people.
    2020 Chippu Summit, the future of the health industry in an epidemic era

    Read more

  • 7月11日:2020年奇普峰会,未来卫生产业在流行时代
    All day
    2020.07.11

    卫生产业被认为是最能抵御经济周期的永恒朝阳产业,但由于它与国家政策和社会民生密切相关,也意味着创新和创业的门槛更高。

    “健康行业需要一个机会来收集价值创新案例,并为投资者和企业家的未来提供灵感。

    在这个瞬息万变的时代和现状中,你会看到卫生行业领导者的想法:
    • 如何判断行业的发展趋势并取得快速进展?
    • 如何面对产业转型和重生的趋势?
    • 如何利用时代的发展浪潮来打破和扩展?
    • 如何完善工业价值体系,将蚕变成蝴蝶?
    2020年奇普峰会,你们在这里会见到这群人,加入这群人。
    2020 年奇普峰会,流行病时代卫生行业的未来

    详情请点击

12
13
14
15
16
  • July 16: SAVE THE DATE—One Year Anniversary (Johnson & Johnson Innovation)
    All day
    2020.07.16

    One year Anniversary Panel Description

    In June 2019, Johnson & Johnson Innovation- in collaboration with the Shanghai Municipal Government, Pudong New Area Governmant, and shanghai Pharma Engine Company, Ltd. Opened JLABS @Shanghai as the first JLABS facility in Asia Pacific and largest in its global network of 13 life science incubators.

    Register here

    In celebration of JLABS @ Shanghai’s first aniversary, we’ve gathered senior leaders from across Johnson & Johnson to discuss how the company is talking on the challenges of COVID-19 and nurturing innovation through active collaboration in an open innovation model.

    Join in recognizing this special One Year Anniversary!

  • 7月16日:一周年纪念活动(强生)
    All day
    2020.07.16

    与强生[email protected]上海携手构建亚太创新生态系统

    2019年6月,强生创新与上海市政府、浦东新区政府、上海医药发动机有限公司合作。 开放的@SHANGHAI作为亚太地区第一个JLABS设施,也是其全球13个生命科学孵化器网络中规模最大的。

    在此处注册

    为了庆祝JLABS——上海的第一个周年纪念日,我们召集了来自强生公司各地的高级领导,讨论公司如何谈论COVID-19的挑战,并通过开放创新模式的积极合作来培育创新。

    加入承认这个特殊的一周年!

  • July 16th – July 17th: Global Pharmaceutical Industry Corporate Equity and Technology Cooperation Trading Conference(Beijing)
    All day
    2020.07.16-2020.07.17

    The 57th Pharmaceutical Futures Exchange will be held on July 16-17, 2020 in Yizhuang, Beijing. Help pharmaceutical companies, commercial companies, new drug development companies, and clinical CRO companies to meet the needs of equity cooperation and new drug technology transfer and R & D outsourcing business

    • Expert group (partial)
    • Zhang Ziran: Vice President of China Chemical and Pharmaceutical Industry Association, Director of the Policy and Regulations Special Committee and Director of the Listed Companies Special Committee
    • Duan Jidong: Chairman of Beijing Times Strategy Enterprise Management Consulting Co., Ltd.
    • Dr. He Shengjiang: Chairman of Guangzhou Iger Biotechnology Co., Ltd.
    • Dr. Yongqing Chen: Chairman of Guoxin Pharmaceutical Technology (Beijing) Co., Ltd.
    • Tian Yuan: Chairman of Guangzhou Renheng Pharmaceutical Technology Co., Ltd.
    • Dr. Li Jing: Chairman of Yaodu Jingwei Information Technology (Beijing) Co., Ltd.
    • Dr. Ma Renqiang: Managing Director of Guangzhou Boji Pharmaceutical Biotechnology Co., Ltd.
    • Wang Dongwei: Deputy General Manager of Beijing Kang Li Consulting Service Co., Ltd.
    • Dr. Yang Shiwei: New Drug R & D Department of Hefei Huafang Pharmaceutical Co., Ltd.

  • July 16: COVID-19 and expedited approval of therapeutic goods – a global perspective
    8:00 am-9:00 am
    2020.07.16

    Hosted by Hall & Wilcox via their corporate zoom platform, join global leaders as they delve into what the regulators (TGA, FDA and European Medicines Agency) are doing to facilitate the supply of therapeutic goods to market quickly due to COVID-19.
    BiotechTalks is offered by the industry for the industry, and enables the Australian biotechnology industry to stay connected, present ideas, projects and updates, and exchange knowledge from home office to home office. 

    Date: Thursday, 16 July 2020
    Time: 8:00am – 9:00am (AEST)

    Registrations

  • 7 月 16 日: COVID-19 和加速批准治疗产品 – 全球视角
    8:00 am-9:00 am
    2020.07.16

    由霍尔和威尔科克斯通过他们的企业变焦平台主办,与全球领导者一起深入探讨监管机构(TGA、FDA和欧洲药品管理局)在 COVID-19 下为方便治疗性产品快速进入市场所做的工作。
    BiotechTalks由业界为该行业提供,使澳大利亚生物技术行业能够保持联系,提出想法、项目和更新,并交流从家庭办公室到家庭办公室的知识。

    日期:2020年7月16日,星期四
    时间:上午 8:00 – 上午 9:00 (AEST)

    注册

  • More events
    • July 16: SAVE THE DATE---One Year Anniversary (Johnson & Johnson Innovation)
      All day
      2020.07.16

      One year Anniversary Panel Description

      In June 2019, Johnson & Johnson Innovation- in collaboration with the Shanghai Municipal Government, Pudong New Area Governmant, and shanghai Pharma Engine Company, Ltd. Opened JLABS @Shanghai as the first JLABS facility in Asia Pacific and largest in its global network of 13 life science incubators.

      Register here

      In celebration of JLABS @ Shanghai’s first aniversary, we’ve gathered senior leaders from across Johnson & Johnson to discuss how the company is talking on the challenges of COVID-19 and nurturing innovation through active collaboration in an open innovation model.

      Join in recognizing this special One Year Anniversary!

    • 7月16日:一周年纪念活动(强生)
      All day
      2020.07.16

      与强生[email protected]上海携手构建亚太创新生态系统

      2019年6月,强生创新与上海市政府、浦东新区政府、上海医药发动机有限公司合作。 开放的@SHANGHAI作为亚太地区第一个JLABS设施,也是其全球13个生命科学孵化器网络中规模最大的。

      在此处注册

      为了庆祝JLABS——上海的第一个周年纪念日,我们召集了来自强生公司各地的高级领导,讨论公司如何谈论COVID-19的挑战,并通过开放创新模式的积极合作来培育创新。

      加入承认这个特殊的一周年!

    • July 16th - July 17th: Global Pharmaceutical Industry Corporate Equity and Technology Cooperation Trading Conference(Beijing)
      All day
      2020.07.16-2020.07.17

      The 57th Pharmaceutical Futures Exchange will be held on July 16-17, 2020 in Yizhuang, Beijing. Help pharmaceutical companies, commercial companies, new drug development companies, and clinical CRO companies to meet the needs of equity cooperation and new drug technology transfer and R & D outsourcing business

      • Expert group (partial)
      • Zhang Ziran: Vice President of China Chemical and Pharmaceutical Industry Association, Director of the Policy and Regulations Special Committee and Director of the Listed Companies Special Committee
      • Duan Jidong: Chairman of Beijing Times Strategy Enterprise Management Consulting Co., Ltd.
      • Dr. He Shengjiang: Chairman of Guangzhou Iger Biotechnology Co., Ltd.
      • Dr. Yongqing Chen: Chairman of Guoxin Pharmaceutical Technology (Beijing) Co., Ltd.
      • Tian Yuan: Chairman of Guangzhou Renheng Pharmaceutical Technology Co., Ltd.
      • Dr. Li Jing: Chairman of Yaodu Jingwei Information Technology (Beijing) Co., Ltd.
      • Dr. Ma Renqiang: Managing Director of Guangzhou Boji Pharmaceutical Biotechnology Co., Ltd.
      • Wang Dongwei: Deputy General Manager of Beijing Kang Li Consulting Service Co., Ltd.
      • Dr. Yang Shiwei: New Drug R & D Department of Hefei Huafang Pharmaceutical Co., Ltd.

    • July 16: COVID-19 and expedited approval of therapeutic goods - a global perspective
      8:00 am-9:00 am
      2020.07.16

      Hosted by Hall & Wilcox via their corporate zoom platform, join global leaders as they delve into what the regulators (TGA, FDA and European Medicines Agency) are doing to facilitate the supply of therapeutic goods to market quickly due to COVID-19.
      BiotechTalks is offered by the industry for the industry, and enables the Australian biotechnology industry to stay connected, present ideas, projects and updates, and exchange knowledge from home office to home office. 

      Date: Thursday, 16 July 2020
      Time: 8:00am – 9:00am (AEST)

      Registrations

    • 7 月 16 日: COVID-19 和加速批准治疗产品 - 全球视角
      8:00 am-9:00 am
      2020.07.16

      由霍尔和威尔科克斯通过他们的企业变焦平台主办,与全球领导者一起深入探讨监管机构(TGA、FDA和欧洲药品管理局)在 COVID-19 下为方便治疗性产品快速进入市场所做的工作。
      BiotechTalks由业界为该行业提供,使澳大利亚生物技术行业能够保持联系,提出想法、项目和更新,并交流从家庭办公室到家庭办公室的知识。

      日期:2020年7月16日,星期四
      时间:上午 8:00 – 上午 9:00 (AEST)

      注册

17
  • 7月17日:金斯瑞细胞基因治疗产业发展与合作论坛首批嘉宾露出|与行业领导者共话产业未来
    All day
    2020.07.17

    细胞/基因技术,成为了继手术、放化疗、靶向药之后的后起新秀,被誉为是唯一可以击败癌症的疗法,因此,国内外对细胞/基因领域的科研投入和资金投入,让细胞/基因领域成为了“重头戏”。

    点击下方图片,了解更多详情

    提到细胞/基因疗法,就必须谈规模化,规模化能力是所有技术走向成熟的重中之重。这一领域患者的情况千差万别,工艺流程非常复杂,产品受到严格监管,对规模化的要求也给了企业不少压力,尽管在架构、测试和迭代能力,技术创新等方面,中国都遥遥领先,但从商业、监管和生产的角度看,我国市场虽然庞大,将科技创新转化为规模化生产,让更多患者能够用得起细胞/基因疗法,恐怕在实践上还需时日。

    强生(中国)投资有限公司亚太创新中心资深总监戴晗、华润正大基金董事总经理柳达、上海泽润生物科技有限公司常务副总裁曾宪放博士、广东香雪精准医疗技术有限公司副总裁龚海平博士等该领域资深从业者和行业领袖,对未来细胞/基因治疗商业化该如何走、走向哪里展开深入探讨。

    届时,基因疗法领航者AskBio公司联合创始人肖啸博士;国内应用免疫学与基因质量领域知名专家、传奇生物首席科学官范晓虎博士;上海药明巨诺生物科技有限公司首席执行官、联合创始人李怡平博士;河南抗癌协会肿瘤生物治疗专业委员会主任、郑州大学第一附属医院生物细胞治疗中心主任张毅教授等人将现身会场,与您面对面分享内部经验,共商细胞基因治疗产业化未来之路。

    金斯瑞“细胞基因治疗产业发展与合作论坛”还特邀默克副总裁、工艺解决方案理中国区总经理Ian Carmichael、金斯瑞质量控制副总裁Fredy Chu等人进行主题演讲,从客户的角度出发,围绕大家都关心的工艺技术、法规政策、质量质控、成本控制等多个问题,设立多角度进行主旨演讲,分享他们的宝贵经验。

18
  • 2020中国细胞生物资源与创新医药应用峰会
    All day
    2020.07.18-2020.07.19

    2nd China Cell Therapy and Innovative Drug Development Summit

    由中国卫生信息与健康医疗大数据学会细胞生物资源与医药创新联合会主办,bioSeedin柏思荟承办的“细胞治疗技术与创新药物开发——第二届中国细胞生物资源与创新医药应用峰会”,将于7月18-19日在上海举行。

    • 权威解读:主办方“中国卫生信息与健康医疗大数据学会细胞生物资源与医药创新联合会”隶属于国家卫生健康委员会直属一级学会。本次大会将邀请卫健委专家、CDE宣讲团专家,权威解读政策法规,推动细胞生物产业化发展。

    • 立足研发:大会邀请研发技术大拿与专家,从实验细节深度解读细胞制备、储存与应用的生产工艺、产品质量控制与评价。

    • 落地临床:聆听一线医生讲述干细胞,CAR-T,NK等各种细胞技术在临床治疗中的应用、数据与效果。

    • 优质听众:联合会拥有200+优秀企业会员,bioSeedin柏思荟拥有1500+精准听众,良好的口碑所带来的参会者高“回头率”。

    大会嘉宾(部分)

    周琪:中科院院士

    韩忠朝:法国国家技术科学院院士、法国国家医学科学院外籍通讯院士

    何如意:国投创新投资管理有限公司首席科学家

    唐民皓:上海市食品安全研究会会长、上海市食药监管局原副局长

    高晨燕:国家药品监督管理局药品审评中心
    生物制品临床部部长

    韩为东:解放军总医院分子免疫学研究室
    生物治疗病区主任

19
20
21
22
  • BIO Asia–Taiwan 2020 Online + Live.
    All day
    2020.07.22-2020.07.26

    REGISTRATION

    BIO Asia–Taiwan 2020 Online + Live. This event will be the first and biggest major industry gathering in Asia since the onset of this global pandemic crisis. With the biomedical industry at the frontline driving discoveries and developments to combat the pandemic, opportunities are ripe for partnering, raising funds, and making deals.

  • 亞洲生技线上大會
    All day
    2020.07.22-2020.07.26

    点击此报名

    BIO Asia–Taiwan 2020 Online + Live. 这将是疫情期间亚洲第一个全球性的大型生物科技国际会议。今年亚洲生技大会的主题是「危难中找寻生机」(Finding Cures in the Crisis)。纵使疫情严峻,生技产业还是要努力经营下去;越是隔离封城,越需要走出去洽谈合作和募资;更何况在面对疫情的危难时,全球生技医药的共同合作益加重要。

23
24
25
26
27
28
29
30
31
August